Myriad Genetics Reports 2% Revenue Growth in Q1, Reiterates 2026 Guidance Amid New Product Launches
summarizeSummary
Myriad Genetics reported first-quarter 2026 financial results, showing a 2% year-over-year revenue increase to $200.4 million, a positive shift from the 2% decline reported in the full year 2025. The company reiterated its full-year 2026 financial guidance, signaling confidence despite reporting a GAAP net loss of $34.1 million ($0.36 per share) and negative adjusted free cash flow of $(19.9) million. Key operational highlights include the launch of Precise Molecular Residual Disease (MRD) and FDA approval for its MyChoice CDx test, alongside progress on an AI-enabled prostate cancer test. While revenue growth and product advancements are positive, the continued net losses and cash burn remain areas of concern for investors, especially given the company's existing $200 million universal shelf registration. Traders will watch for further progress in the Cancer Care Continuum business and improvements in cash flow.
At the time of this announcement, MYGN was trading at $4.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $470.3M. The 52-week trading range was $3.76 to $8.59. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.